Stelara shows efficacy in real-world study

After 52 weeks of treatment, Stelara helped induce clinical and endoscopic remission in patients with refractory Crohn’s disease, according to study results.
Marisa Iborra, MD, PhD, from Hospital Universitari Politecnic La Fe in Spain, and colleagues wrote that there is little research on the long-term safety and efficacy of Stelara (ustekinumab, Janssen), using data taken from daily clinical practice.
“Although these studies confirm the effectiveness and safety of ustekinumab in CD patients refractory to many treatments, the number of patients analyzed in the long-term follow-up is

Source link

Related posts

circHECTD1 facilitates glutaminolysis to promote gastric cancer progression by targeting miR-1256 and activating β-catenin/c-Myc signaling


The p300/YY1/miR-500a-5p/HDAC2 signalling axis regulates cell proliferation in human colorectal cancer


Pancreas Divisum and Pancreatitis: Is Sphincterotomy Worth It?


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World